Diabetologie und Stoffwechsel 2019; 14(S 01): S84
DOI: 10.1055/s-0039-1688353
Poster
SGLT2-Inhibitoren und GLP1-Agonisten
Georg Thieme Verlag KG Stuttgart · New York

Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs. exenatide and dulaglutide in type 2 diabetes

M Nauck
1   Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University, Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University, Bochum, Germany
,
R de la Rosa
2   Four Rivers Clinical Research, Four Rivers Clinical Research, Paducah, KY, United States
,
M Marre
3   Hôpital Bichat-Claude Bernard, Hôpital Bichat-Claude Bernard, Paris, France
,
V Woo
4   Univeristy of Manitoba, Univeristy of Manitoba, Winnipeg, MB, Canada
,
T Hansen
5   Novo Nordisk A/S, Novo Nordisk A/S, Søborg, Denmark
,
J Larsen
5   Novo Nordisk A/S, Novo Nordisk A/S, Søborg, Denmark
,
E Yildirim
5   Novo Nordisk A/S, Novo Nordisk A/S, Søborg, Denmark
,
J Wilding
6   University of Liverpool, University of Liverpool, Liverpool, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
07 May 2019 (online)

Also available at
 

Background:

Semaglutide showed superior HbA1c and body weight reductions vs. comparators in SUSTAIN clinical trials. A analysis showed the contribution of nausea or vomiting to superior body weight loss with semaglutide in SUSTAIN 1 – 5 was small. This post hoc analysis assessed the contribution of nausea or vomiting to the greater weight loss with semaglutide vs. exenatide extended-release (ER) and dulaglutide.

Materials:

Subjects with T2D were randomised to semaglutide 1.0 mg vs. exenatide ER 2.0 mg in SUSTAIN 3 or semaglutide 1.0 mg vs. dulaglutide 1.5 mg and semaglutide 0.5 mg vs. dulaglutide 0.75 mg in SUSTAIN 7. A mediation analysis was done to determine how much of the estimated treatment differences in weight loss was due to direct effects of semaglutide vs. nausea or vomiting.

Results:

In SUSTAIN 3, proportions of subjects experiencing nausea or vomiting were 24.0 (semaglutide) vs. 14.1% (exenatide ER). In SUSTAIN 7, 24.0 vs. 23.1% (semaglutide 1.0 mg vs. dulaglutide 1.5 mg). In SUSTAIN 7, mean changes in body weight from baseline were -7.6 vs. -3.9 kg (semaglutide 1.0 mg vs. dulaglutide 1.5 mg) in those with nausea or vomiting, and -6.2 vs. -2.7 kg (semaglutide 1.0 mg vs. dulaglutide 1.5 mg) in those without.

Conclusion:

In SUSTAIN 3 and 7, body weight reductions were significantly greater with semaglutide vs. exenatide ER and dulaglutide in subjects with and without nausea or vomiting. Nausea or vomiting contributed minimally to the superior weight reductions.